New chelating agent reduces toxicity in PSMA radiopharmaceutical therapy
Toronto, Ontario—A newly developed chelator can significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to research...
